Company intelligence / Profile preview
Eccogene
Shanghai, Shanghai, Chinaeccogene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase 1 clinical trials for multiple programs including ECC5004 (GLP-1RA), ECC4703 (THR-β agonist), and ECC0509 (SSAO/VAP-1 inhibitor)
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersImmunologyEndocrinology
- Modalities
- Oral small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
AstraZeneca (licensed ECC5004/AZD5004)
Beyond the preview
Go deeper on Eccogene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eccogene.